Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center in Herat, Afghanistan
- PMID: 37619213
- PMCID: PMC10449473
- DOI: 10.1371/journal.pgph.0001687
Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center in Herat, Afghanistan
Abstract
Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), such as Afghanistan are sparse. To describe clinical characteristics, severity, and outcomes of patients hospitalized in the MSF COVID-19 treatment center (CTC) in Herat, Afghanistan and to assess risk factors associated with severe outcomes. 1113 patients were included in this observational study between June 2020 and April 2022. Descriptive analysis was performed on clinical characteristics, complications, and outcomes of patients. Univariate description by Cox regression to identify risk factors for an adverse outcome was performed. Adverse outcome was defined as death or transfer to a level 3 intensive care located at another health facility. Finally, factors identified were included in a multivariate Cox survival analysis. A total of 165 patients (14.8%) suffered from a severe disease course, with a median time of 6 days (interquartile range: 2-11 days) from admission to adverse outcome. In our multivariate model, we identified male gender, age over 50, high O2 flow administered during admission, lymphopenia, anemia and O2 saturation < = 93% during the first three days of admission as predictors for a severe disease course (p<0.05). Our analysis concluded in a relatively low rate of adverse outcomes of 14.8%. This is possibly related to the fact that the resources at an MSF-led facility are higher, in terms of human resources as well as supply of drugs and biomedical equipment, including oxygen therapy devices, compared to local hospitals. Predictors for severe disease outcomes were found to be comparable to other settings.
Copyright: © 2023 Klein et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600. doi: 10.1002/14651858.CD013600.pub2. PMID: 32406927 Free PMC article. Updated.
-
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).Trials. 2021 Jan 4;22(1):1. doi: 10.1186/s13063-020-04976-x. Trials. 2021. PMID: 33397449 Free PMC article.
-
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.J Epidemiol Glob Health. 2020 Sep;10(3):214-221. doi: 10.2991/jegh.k.200806.002. J Epidemiol Glob Health. 2020. PMID: 32954712 Free PMC article.
-
Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study.Glob Heart. 2022 Jun 15;17(1):40. doi: 10.5334/gh.1128. eCollection 2022. Glob Heart. 2022. PMID: 35837356 Free PMC article.
References
-
- Organization WH. WHO Coronavirus (COVID-19) Dashboard [Available from: https://covid19.who.int.
-
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. - PubMed
-
- Organization WH. Living guidance for clinical management of COVID-19 2021. [cited 2022 10.08.2022]. Available from: https://apps.who.int/iris/bitstream/handle/10665/349321/WHO-2019-nCoV-cl....
-
- Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al.. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods—United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):146–52. doi: 10.15585/mmwr.mm7104e4 - DOI - PMC - PubMed
-
- Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al.. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35–42. doi: 10.1016/S1473-3099(21)00475-8 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous